Castle Biosciences (CSTL) Capital Expenditures (2018 - 2026)

Castle Biosciences has disclosed Capital Expenditures across 9 years of filings, most recently posting $12.5 million for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $12.5 million, up 287.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.4 million (up 350.83% YoY), and the FY2025 annual result was $2.1 million, changed N/A from the prior year.
• Capital Expenditures came in at $12.5 million for Q1 2026 at Castle Biosciences, up from -$26.7 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $22.0 million in Q3 2025 to a low of -$26.7 million in Q4 2025.
• The 5-year median for Capital Expenditures is $3.2 million (2025), against an average of $1.7 million.
• Across the five-year window, Capital Expenditures surged 10331.25% in 2023 and plunged 647.3% in 2024, its largest moves.
• Castle Biosciences' Capital Expenditures stood at -$2.4 million in 2022, then jumped by 254.88% to $3.8 million in 2023, then tumbled by 647.3% to -$20.8 million in 2024, then fell by 28.73% to -$26.7 million in 2025, then jumped by 146.61% to $12.5 million in 2026.
• The last three Capital Expenditures figures came in at $12.5 million (Q1 2026), -$26.7 million (Q4 2025), and $22.0 million (Q3 2025), per Business Quant data.